X4 Pharmaceuticals Inc. Common Stock (XFOR)
Stock · NASDAQ · Health Care
$2.59as of 10/16/2026
Price chart
Active signals
XFOR Signal Track Record
How signals performed across all stocks →What XFOR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -3.9% | 44% | September 23, 2026 |
| Bollinger Band Breakout | 23 | -12.9% | 26% | August 7, 2026 |
| Bollinger Band Breakdown | 20 | +7.1% | 60% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +10.7% | 63% | July 16, 2026 |
| Any 20-session window (baseline) | -5.6% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis s…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 45
- Website
- www.x4pharma.com/
Fundamentals
- 1-day range
- $2.52$2.71
- Market cap
- $393.31M
- P/E (trailing)
- 3.24
- P/E (forward)
- -3.37
- EPS (trailing)
- $-1.24
- Dividend yield
- —
- Beta
- 0.50
- Avg. volume
- 838.2K
- Dividend pay date
- March 14, 2019
How X4 Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
X4 Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
- STROSutro Biopharma Inc. Common Stock$10.94▼ 4.54%Market cap $400.18MP/E —$7.15$43.85
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
| STRO Sutro Biopharma Inc. Common Stock | $400.18M | — | $10.94 | ▼ 4.54% | $7.15$43.85 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersYahoo · 10/9/2026
- X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVenturesYahoo · 10/8/2026
- X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesYahoo · 10/8/2026
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/1/2026
- Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a TurnaroundYahoo · 9/24/2026
- X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo · 9/11/2026
Insider Activity
Insider Actions →- David Kirske · October 1, 2026 · Sale11.8K @ $2.86
- John Volpone · August 12, 2026 · Sale24.6K @ $4.44
- Adam R. Craig · August 12, 2026 · Sale47.4K @ $4.44
- Kelly Gold · July 1, 2026 · Grant110.0K
- David Kirske · June 30, 2026 · Sale8.5K @ $4.26
- David Kirske · May 12, 2026 · Sale17.0K @ $4.29
Institutional Ownership
March 31, 2026
- Total shares held
- 89.91M
- Total value held
- $371.50M
- Institutional holders
- 78
- Unknown9.47M
- Unknown8.94M
- Unknown8.10M
- Unknown7.97M
- Unknown6.74M
- Unknown6.46M
- Unknown6.34M
- Unknown3.72M
- Unknown3.50M
- Unknown3.27M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.